Anika Therapeutics
ANIK
165 hedge funds and large institutions have $574M invested in Anika Therapeutics in 2019 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 55 increasing their positions, 51 reducing their positions, and 21 closing their positions.
453% more call options, than puts
Call options by funds: $4.6M | Put options by funds: $832K
57% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 21
42% more capital invested
Capital invested by funds: $404M → $574M (+$170M)
5.61% more ownership
Funds ownership: 93.85% → 99.46% (+5.6%)
5% more funds holding
Funds holding: 157 → 165 (+8)
8% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$13M |
| 2 |
Goldman Sachs
New York
|
+$5.49M |
| 3 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$3.93M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.7M |
| 5 |
Natixis Advisors
Boston,
Massachusetts
|
+$3.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
-$6.22M |
| 2 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$3.52M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.31M |
| 4 |
JG
Jefferies Group
New York
|
-$3.12M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.76M |
ANIK Hedge Fund Activity: Q2 2019 in Review
165 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2019, worth a combined $574M — up 42% from $404M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ANIK positions and 21 closed out — a net gain of 12 holders — while 55 added to existing stakes and 51 trimmed.
The largest buyer was Ameriprise, adding an estimated $13M. The largest seller was THB Asset Management, exiting entirely with an estimated $6.22M sold.
- 165 institutional investors held Anika Therapeutics (ANIK) as of Q2 2019, up from 157 in Q1 2019.
- Funds reported $574M of Anika Therapeutics stock for Q2 2019, up 42% quarter-over-quarter.
- 33 funds opened new Anika Therapeutics positions in Q2 2019 and 21 closed out, a net change of +12 holders.
- The largest Anika Therapeutics buyer in Q2 2019 was Ameriprise, an estimated $13M added.
- The largest Anika Therapeutics seller in Q2 2019 was THB Asset Management, an estimated $6.22M sold.
Based on aggregated 13F filings for Q2 2019.